The Liofilchem® MTS™ (MIC Test Strip) is a quantitative method intended for the in vitro determination ofantimicrobial susceptibility ofbacteria MTS™ consists ofspecialized papyr impregnated with a pre-defined concentration gradient ofan antimicrobial agent, which is used todetermine the minimum inhibitozy concentration (MIC) in µglmL ofantimicrobial agents against bacteria as tested on agar media using ovemightincubation and manual reading procedures. The MTS™ Plazomicin at concentrations of0.016-256 µglmL should be interpreted at 16-20 hours ofincubation.MTS™ PLZ can be used to dete1mine the MIC ofplazomicin against the microorganisms listed below:Plazomicin Activity According to the FDA LabelClinical and in vitroEnterobacter cloacaeEscherichia coliKlebsiella pneumoniaeProteus mirabilisin vitro onlyCitrobacterfreundiiCitrobacter koseriKlebsiella (Enterobacter) aerogenesKlebsiella oxytocaMorganella morganiiProteus vulgarisProvidencia stuartiiSerratia marcescens

The Liofilchem® MTS™ (MIC Test Strip) is a quantitative method intended for the in vitro determination ofantimicrobial susceptibility ofbacteria MTS™ consists ofspecialized papyr impregnated with a pre-defined concentration gradient ofan antimicrobial agent, which is used todetermine the minimum inhibitozy concentration (MIC) in µglmL ofantimicrobial agents against bacteria as tested on agar media using ovemightincubation and manual reading procedures. The MTS™ Plazomicin at concentrations of0.016-256 µglmL should be interpreted at 16-20 hours ofincubation.MTS™ PLZ can be used to dete1mine the MIC ofplazomicin against the microorganisms listed below:Plazomicin Activity According to the FDA LabelClinical and in vitroEnterobacter cloacaeEscherichia coliKlebsiella pneumoniaeProteus mirabilisin vitro onlyCitrobacterfreundiiCitrobacter koseriKlebsiella (Enterobacter) aerogenesKlebsiella oxytocaMorganella morganiiProteus vulgarisProvidencia stuartiiSerratia marcescens

MTS™ (MIC Test Strip) Levofloxacin 0.002-32 μg/mL is a quantitative method intended for the in vitro determination of antimicrobial susceptibility of bacteria. MTS™ consists of specialized paper impregnated with a pre-defined concentration gradient of an antimicrobial agent, which is used to determine the minimum inhibitory concentration (MIC) in μg/mL of antimicrobial agents against bacteria as tested on agar media using overnight incubation and manual reading procedures.MTS™ Levofloxacin at concentrations of 0.002-32 μg/mL should be interpreted at 16-20 hours of incubation.MTS™ Levofloxacin can be used to determine the MIC of levofloxacin against the following bacteria.Levofloxacin has been shown to be active both clinically and in vitro against these bacterial species according to the FDA drug approved label:Gram-negative bacteriaEnterobacter cloacaeEscherichia coliKlebsiella pneumoniaeProteus mirabilisPseudomonas aeruginosaSerratia marcescensLevofloxacin has been shown to be active in vitro only against the non-fastidious bacteria listed below according to the FDA drug approved label:Citrobacter freundiiCitrobacter koseriKlebsiella aerogenesKlebsiella oxytocaMorganella morganiiProteus vulgarisProvidencia rettgeriProvidencia stuartii

MTS™ (MIC Test Strip) Levofloxacin 0.002-32 μg/mL is a quantitative method intended for the in vitro determination of antimicrobial susceptibility of bacteria. MTS™ consists of specialized paper impregnated with a pre-defined concentration gradient of an antimicrobial agent, which is used to determine the minimum inhibitory concentration (MIC) in μg/mL of antimicrobial agents against bacteria as tested on agar media using overnight incubation and manual reading procedures.MTS™ Levofloxacin at concentrations of 0.002-32 μg/mL should be interpreted at 16-20 hours of incubation.MTS™ Levofloxacin can be used to determine the MIC of levofloxacin against the following bacteria.Levofloxacin has been shown to be active both clinically and in vitro against these bacterial species according to the FDA drug approved label:Gram-negative bacteriaEnterobacter cloacaeEscherichia coliKlebsiella pneumoniaeProteus mirabilisPseudomonas aeruginosaSerratia marcescensLevofloxacin has been shown to be active in vitro only against the non-fastidious bacteria listed below according to the FDA drug approved label:Citrobacter freundiiCitrobacter koseriKlebsiella aerogenesKlebsiella oxytocaMorganella morganiiProteus vulgarisProvidencia rettgeriProvidencia stuartii

MTS is a quantitative assay for determining the Minimum Inhibitory Concentration (M.I.C.) of antimicrobial agents against microorganisms. Liofilchem MIC Test Strip Penicillin G 0.002-32 µg/mL are specialized strips impregnated with a predefined concentration gradient of Penicillin G for susceptibility testing of Streptococcus ssp.

MTS is a quantitative assay for determining the Minimum Inhibitory Concentration (M.I.C.) of antimicrobial agents against microorganisms. Liofilchem MIC Test Strip Penicillin G 0.002-32 µg/mL are specialized strips impregnated with a predefined concentration gradient of Penicillin G for susceptibility testing of Streptococcus ssp.

The MTS™ Tetracycline 0.016-256 μg/mL is a quantitative method intended for the in vitro determination of antimicrobial susceptibility of bacteria. MTS™ consists of specialized paper impregnated with a pre-defined concentration gradient of an antimicrobial agent, which is used to determine the minimum inhibitory concentration (MIC) in μg/mL of antimicrobial agents against bacteria as tested on agar media using overnight incubation and manual reading procedures. The MTS™ Tetracycline at concentrations of 0.016-256 μg/mL should be interpreted at 16-20 hours of incubation.Tetracycline has been shown to be active both clinically and in vitro against these bacterial species according to the FDA drug approved label:Staphylococcus aureusAcinetobacter baumanniiEscherichia coliKlebsiella aerogenesKlebsiella oxytocaKlebsiella pneumoniae

The MTS™ Tetracycline 0.016-256 μg/mL is a quantitative method intended for the in vitro determination of antimicrobial susceptibility of bacteria. MTS™ consists of specialized paper impregnated with a pre-defined concentration gradient of an antimicrobial agent, which is used to determine the minimum inhibitory concentration (MIC) in μg/mL of antimicrobial agents against bacteria as tested on agar media using overnight incubation and manual reading procedures. The MTS™ Tetracycline at concentrations of 0.016-256 μg/mL should be interpreted at 16-20 hours of incubation.Tetracycline has been shown to be active both clinically and in vitro against these bacterial species according to the FDA drug approved label:Staphylococcus aureusAcinetobacter baumanniiEscherichia coliKlebsiella aerogenesKlebsiella oxytocaKlebsiella pneumoniae

MIC Test Strip is a quantitative assay for determining the Minimum Inhibitory Concentration (M.I.C.) of antimicrobial agents against microorganisms. Liofilchem MIC Test Strip Linezolid 0.016 – 256 μg/mL are specialized strips impregnated with a predefined concentration gradient of Linezolid for susceptibility testing of Staphylococcus aureus (including methicillin-resistant isolates), Enterococcus faecium (vancomycin resistant isolates only).

MIC Test Strip is a quantitative assay for determining the Minimum Inhibitory Concentration (M.I.C.) of antimicrobial agents against microorganisms. Liofilchem MIC Test Strip Linezolid 0.016 – 256 μg/mL are specialized strips impregnated with a predefined concentration gradient of Linezolid for susceptibility testing of Staphylococcus aureus (including methicillin-resistant isolates), Enterococcus faecium (vancomycin resistant isolates only).

MIC Tests Strip is a quantitative assay for determining the Minimum Inhibitory Concentration (M.I.C.) of antimicrobial agents against microorganisms. Liofilchem MIC Test Strip Ceftazidime-avibactam 0.016/4 – 256 /4 µg/mL are specialized strips impregnated with a predefined concentration gradient of Ceftazidime and Avibactam for susceptibility testing of Citrobacter freundii, Enterobacter cloacae, Escherichia Coli, Klebsiella oxytoca, Klebsiella pneumoniae, Proteus mirabilis and Pseudomonas aeruginosa.

MIC Tests Strip is a quantitative assay for determining the Minimum Inhibitory Concentration (M.I.C.) of antimicrobial agents against microorganisms. Liofilchem MIC Test Strip Ceftazidime-avibactam 0.016/4 – 256 /4 µg/mL are specialized strips impregnated with a predefined concentration gradient of Ceftazidime and Avibactam for susceptibility testing of Citrobacter freundii, Enterobacter cloacae, Escherichia Coli, Klebsiella oxytoca, Klebsiella pneumoniae, Proteus mirabilis and Pseudomonas aeruginosa.

The Liofilchem® MTS™ (MIC Test Strip) Eravacycline 0.002-32 µg/mL is a quantitative method intended for the in vitro determination of antimicrobial susceptibility ofbacteria. MTS™ consists of specialized paper impregnated with a pre-defined concentration gradient of an antimicrobial agent, which is used todetermine the minimum inhibitory concentration (MIC) in µglmL of antimicrobial agents against bacteria as tested on agar media using ovemightincubation and manual reading procedures. The MTS™ Eravacycline at concentrations of 0.002-32 µglmL should be interpreted at 16-20 hours ofincubation.MTS™ Eravacycline can be used to dete1mine the MIC of eravacycline against the following bacteria.Eravacycline has been shown to be active both clinically and in vitro against these bacterial species accoring to the FDA drug approved label:Gram-positive bacteriaEnterococcus faecalisEnterococcus faeciumStaphylococcus aureusGram-negative bacteriaCitrobacter freundiiEnterobacter cloacaeEscherichia coliKlebsiella oxytocaKlebsiella pneumoniaeEravacycline has been shown to be active in vitro only against the non-fastidious bacteria listed below accoring to the FDA drug aprroved label:Citrobacter koseriKlebsiella (Enterobacter) aerogenes

The Liofilchem® MTS™ (MIC Test Strip) Eravacycline 0.002-32 µg/mL is a quantitative method intended for the in vitro determination of antimicrobial susceptibility ofbacteria. MTS™ consists of specialized paper impregnated with a pre-defined concentration gradient of an antimicrobial agent, which is used todetermine the minimum inhibitory concentration (MIC) in µglmL of antimicrobial agents against bacteria as tested on agar media using ovemightincubation and manual reading procedures. The MTS™ Eravacycline at concentrations of 0.002-32 µglmL should be interpreted at 16-20 hours ofincubation.MTS™ Eravacycline can be used to dete1mine the MIC of eravacycline against the following bacteria.Eravacycline has been shown to be active both clinically and in vitro against these bacterial species accoring to the FDA drug approved label:Gram-positive bacteriaEnterococcus faecalisEnterococcus faeciumStaphylococcus aureusGram-negative bacteriaCitrobacter freundiiEnterobacter cloacaeEscherichia coliKlebsiella oxytocaKlebsiella pneumoniaeEravacycline has been shown to be active in vitro only against the non-fastidious bacteria listed below accoring to the FDA drug aprroved label:Citrobacter koseriKlebsiella (Enterobacter) aerogenes